arrow_back Trending Legislation
Share share

Lower Drug Prices: Global Benchmarking and Personal Importation

This bill aims to reduce prescription drug prices in the U.S. by aligning them with international benchmarks. It also facilitates individual importation of drugs, potentially saving patients money. Authorities will also target anti-competitive practices by drug manufacturers.
Key points
U.S. drug prices are to be compared with those in other developed countries to potentially lower costs for patients.
Individuals may be able to import cheaper prescription drugs from other developed countries, if deemed safe.
Authorities will take action against drug manufacturers engaging in anti-competitive practices.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Introduced
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Global Fairness in Drug Pricing Act
Print number: HR 3493
Sponsor: Rep. Khanna, Ro [D-CA-17]
Process start date: 2025-05-19
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Lower Drug Prices: Global Benchmarking and Personal Importation

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 3493.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-05-19.

What are the main provisions?

Key points include:

  • U.S. drug prices are to be compared with those in other developed countries to potentially lower costs for patients.
  • Individuals may be able to import cheaper prescription drugs from other developed countries, if deemed safe.
  • Authorities will take action against drug manufacturers engaging in anti-competitive practices.

What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Khanna, Ro [D-CA-17].

What is the latest detailed status?

The latest detailed status is: Introduced in House

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

Analysis and Potential Impact of HR 3493

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health Economy